N J Vogelzang

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    Nicholas J Vogelzang
    University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA
    J Clin Oncol 21:2636-44. 2003
  2. ncbi request reprint A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma
    Nicholas J Vogelzang
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 100:65-71. 2004
  3. ncbi request reprint A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer
    N J Vogelzang
    Cancer Research Center, University of Chicago, IL 60637 1470, USA
    Invest New Drugs 19:255-60. 2001
  4. ncbi request reprint Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies
    S Mani
    University of Chicago Medical Center, Section of Hematology Oncology, Chicago, Illinois, USA
    Cancer 92:1567-76. 2001
  5. ncbi request reprint Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience
    A S Artz
    University of Chicago Hospitals, Chicago, IL 60637 1470, USA
    Bone Marrow Transplant 35:253-60. 2005
  6. ncbi request reprint Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer
    B I Rini
    Section of Hematology Oncology, University of Chicago Hospitals, IL 60637 1470, USA
    J Clin Oncol 18:2419-26. 2000
  7. ncbi request reprint Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations
    B C Goh
    Section of Hematology/Oncology, Cancer Research Center, University of Chicago, Chicago, IL, USA
    J Clin Oncol 19:1476-84. 2001
  8. ncbi request reprint Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer
    R L Schilsky
    Department of Medicine, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Illinois 60637, USA
    Clin Cancer Res 6:3025-31. 2000
  9. ncbi request reprint A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine
    S D Undevia
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Ann Oncol 15:1705-11. 2004
  10. ncbi request reprint Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer
    N J Vogelzang
    Cancer Research Center, University of Chicago Pritzker School of Medicine, Illinois 60637 1470, USA
    Clin Cancer Res 4:929-34. 1998

Collaborators

Detail Information

Publications99

  1. ncbi request reprint Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    Nicholas J Vogelzang
    University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA
    J Clin Oncol 21:2636-44. 2003
    ..We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone...
  2. ncbi request reprint A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma
    Nicholas J Vogelzang
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 100:65-71. 2004
    ....
  3. ncbi request reprint A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer
    N J Vogelzang
    Cancer Research Center, University of Chicago, IL 60637 1470, USA
    Invest New Drugs 19:255-60. 2001
    ..No responses were seen in 14 patients. The median survival from on study was 16 months (range two to 28 months). At this dose and schedule ranpirnase has minimal activity in metastatic renal cell cancer...
  4. ncbi request reprint Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies
    S Mani
    University of Chicago Medical Center, Section of Hematology Oncology, Chicago, Illinois, USA
    Cancer 92:1567-76. 2001
    ..The purpose of this study was to determine the maximum tolerated dose and toxicity profile of gemcitabine given on a weekly schedule with continuous infusion 5-fluorouracil...
  5. ncbi request reprint Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience
    A S Artz
    University of Chicago Hospitals, Chicago, IL 60637 1470, USA
    Bone Marrow Transplant 35:253-60. 2005
    ..002). NST leads to durable responses in a minority of metastatic RCC patients. Appropriate patient selection is paramount. Anemia and decreased performance status may enable risk stratification...
  6. ncbi request reprint Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer
    B I Rini
    Section of Hematology Oncology, University of Chicago Hospitals, IL 60637 1470, USA
    J Clin Oncol 18:2419-26. 2000
    ..To determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5-FU) in patients with metastatic renal cell carcinoma (RCC)...
  7. ncbi request reprint Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations
    B C Goh
    Section of Hematology/Oncology, Cancer Research Center, University of Chicago, Chicago, IL, USA
    J Clin Oncol 19:1476-84. 2001
    ..CONCLUSION: The recommended dose for ZD9331 on this schedule is 25 mg/d. Neutropenia, thrombocytopenia, and rash were dose-limiting, and efficacy studies in colorectal cancer are indicated...
  8. ncbi request reprint Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer
    R L Schilsky
    Department of Medicine, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Illinois 60637, USA
    Clin Cancer Res 6:3025-31. 2000
    ..Bone marrow suppression, which may be cumulative, is the dose-limiting toxicity of the combination. Prolonged AGT suppression is likely attributable primarily to the effect of O6-benzyl-8-oxoguanine...
  9. ncbi request reprint A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine
    S D Undevia
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Ann Oncol 15:1705-11. 2004
    ..This study was conducted to determine the toxicity profile, maximum tolerated dose (MTD) and pharmacokinetics of the putative histone deacetylase inhibitor CI-994 in combination with capecitabine...
  10. ncbi request reprint Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer
    N J Vogelzang
    Cancer Research Center, University of Chicago Pritzker School of Medicine, Illinois 60637 1470, USA
    Clin Cancer Res 4:929-34. 1998
    ..Curiously, an increase in alkaline phosphatase was associated with an increase in the platelet nadir (P = 0.02). If PZDH continues to be developed as an antineoplastic agent, further studies of these relationships are suggested...
  11. ncbi request reprint Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma
    M Aklilu
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Ann Oncol 15:1109-14. 2004
    ..We postulated that in patients with metastatic renal cell carcinoma (RCC) or melanoma, depletion of normal B cells using the anti-CD20 mAb rituximab before treatment with low-dose interleukin (IL)-2 would improve clinical outcome...
  12. ncbi request reprint Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma
    W M Stadler
    Department of Medicine, University of Chicago, IL 60637, USA
    J Clin Oncol 16:1820-5. 1998
    ....
  13. ncbi request reprint Study of cohort-specific consent and patient control in phase I cancer trials
    C K Daugherty
    Department of Medicine, The MacLean Center for Clinical Medical Ethics, University of Chicago, IL 60637 1470, USA
    J Clin Oncol 16:2305-12. 1998
    ....
  14. ncbi request reprint Kidney cancer
    N J Vogelzang
    University of Chicago Medical Center, Section of Hematology Oncology, IL 60637 1470, USA
    Lancet 352:1691-6. 1998
    ..Therapy for metastatic renal cancer remains inadequate, but recent developments in basic and clinical research suggest future improvement...
  15. ncbi request reprint Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study
    W M Stadler
    University of Chicago and University of Illinois, Chicago, IL, USA
    J Clin Oncol 18:371-5. 2000
    ..Because responses were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of flavopiridol in this patient population...
  16. ncbi request reprint A phase II trial of oral temozolomide in patients with metastatic renal cell cancer
    D K Park
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 50:160-2. 2002
    ..O(6)-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies...
  17. ncbi request reprint Docetaxel and exisulind in hormone-refractory prostate cancer
    C W Ryan
    Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 28:56-61. 2001
    ..Accrual is ongoing...
  18. ncbi request reprint Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer
    R B Ewesuedo
    Committee on Clinical Pharmacology, Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Chicago, IL 60637, USA
    J Clin Oncol 19:2084-90. 2001
    ..Further studies to characterize the pharmacodynamics and pharmacogenetics of TAS-103 are warranted...
  19. ncbi request reprint Gemcitabine in the treatment of bladder cancer
    C W Ryan
    Section of Hematology Oncology, University of Chicago Medical Centre, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Expert Opin Pharmacother 1:547-53. 2000
    ..A randomised trial of gemcitabine plus cisplatin versus M-VAC has completed accrual but has not yet been reported. New combination studies of gemcitabine with other chemotherapy agents, including the taxanes, are ongoing...
  20. ncbi request reprint A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
    A A Desai
    Section of Hematology and Oncology, University of Chicago, Chicago, IL 60637, USA
    Ann Oncol 16:958-65. 2005
    ..Plasma pharmacokinetics of GTI-2040 and suppression of RNR expression in peripheral blood mononuclear cells were also studied...
  21. ncbi request reprint High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
    N J Vogelzang
    University of Chicago, Department of Medicine, IL, USA
    Ann Oncol 10:597-600. 1999
    ..New agents with activity in mesothelioma are sorely needed. The Cancer and Leukemia Group B (CALGB) therefore performed a phase II study of high-dose paclitaxel in patients with malignant mesothelioma who had no prior chemotherapy...
  22. ncbi request reprint Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma
    W M Stadler
    University of Chicago, Northwestern University, and Loyola University of Illinois, USA
    J Clin Oncol 17:2541-5. 1999
    ..Its highly vascular nature suggests that antiangiogenesis therapy might be useful. We thus performed a phase II study of the fumigillin analog TNP-470 in previously treated patients with metastatic renal cell carcinoma...
  23. ncbi request reprint Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B
    H L Kindler
    University of Chicago Medical Center, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Lung Cancer 31:311-7. 2001
    ..The CALGB conducted a phase II multicenter trial to evaluate the activity of gemcitabine in malignant mesothelioma (CALGB protocol 9530)...
  24. ncbi request reprint Emerging insights into the biology and therapy of malignant mesothelioma
    Nicholas J Vogelzang
    University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Semin Oncol 29:35-42. 2002
    ....
  25. ncbi request reprint Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm
    E J Small
    Department of Medicine, University of California, San Francisco 94115, USA
    J Clin Oncol 15:382-8. 1997
    ..To discuss the evolution of new concepts in the Use of second-line hormonal therapy for patients with progressive prostate cancer despite androgen deprivation...
  26. ncbi request reprint A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer
    Andrew Artz
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Am J Clin Oncol 28:109-13. 2005
    ....
  27. ncbi request reprint A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma
    C M George
    Section of Hematology Oncology, Department of Medicine, University of Chicago, IL 60637 1470, USA
    Ann Oncol 13:116-20. 2002
    ..Based upon in vitro synergy of gemcitabine/cisplatin and 5-FU/cisplatin, we hypothesized that the addition of cisplatin could improve the objective response rate of gemcitabine and 5-FU with manageable toxicity...
  28. ncbi request reprint Nilutamide: possible utility as a second-line hormonal agent
    A Desai
    Section of Hematology/Oncology, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Urology 58:1016-20. 2001
    ..CONCLUSIONS: A subset of patients, whose disease progresses with prior antiandrogen therapy, may experience a PSA response to nilutamide. The role of nilutamide in such hormone-resistant patients deserves additional prospective study...
  29. ncbi request reprint Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies
    Christopher W Ryan
    Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
    Clin Cancer Res 10:4406-11. 2004
    ..This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies...
  30. ncbi request reprint Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study
    Nancy B Davis
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    J Clin Oncol 22:115-9. 2004
    ..Determine response rate, time to disease progression, and toxicity of the proteasome inhibitor PS-341 in patients with stage IV renal cell cancer...
  31. ncbi request reprint Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer
    Walter M Stadler
    University of Chicago, Illinois 60637, USA
    J Urol 170:1141-5. 2003
    ..To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series long-term survival as a function of known and suspected prognostic variables was determined...
  32. ncbi request reprint A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer
    Walter M Stadler
    University of Chicago Phase II Consortium, University of Chicago, Section of Hematology Oncology, Chicago, Illinois 60637, USA
    Clin Cancer Res 10:3365-70. 2004
    ..In vitro assessment of SU5416 on PSA secretion was assessed in the LNCaP cell line. Baseline serum basic fibroblast growth factor and plasma vascular endothelial growth factor (VEGF) were explored as prognostic factors...
  33. ncbi request reprint Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
    Med Phys 31:1105-15. 2004
    ..93). We have developed computerized techniques for the measurement of mesothelioma tumor thickness in CT scans. These techniques achieved varying levels of agreement with measurements made by human observers...
  34. ncbi request reprint Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Acad Radiol 12:1301-9. 2005
    ..To evaluate the clinical acceptability of semiautomated methods for the measurement of mesothelioma tumor thickness in computed tomography (CT) scans...
  35. ncbi request reprint Phase I study of an oral formulation of ZD9331 administered daily for 28 days
    Michael B Sawyer
    Committe on Clinical Pharmacology, Department of Medicine, Cancer Research Center and Section of Hematology Oncology, University of Chicago, IL USA
    J Clin Oncol 21:1859-65. 2003
    ..To define the maximum-tolerated dose and dose-limiting toxicities (DLTs) of an oral formulation of ZD9331, a novel thymidylate synthase inhibitor that is not a substrate for folylpolyglutamate synthase...
  36. ncbi request reprint Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer
    James O Jin
    Section of Hematology Oncology, University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 5:150-4. 2006
    ..Despite the general acceptance of gemcitabine/cisplatin in metastatic bladder cancer, its role and tolerability in the adjuvant setting, in which renal insufficiency is common, is unclear...
  37. ncbi request reprint A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer
    Christopher W Ryan
    Department of Medicine, Section of Hematology Oncology, University of Chicago MC2115, 5841S Maryland Ave, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 50:1-5. 2002
    ..The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule...
  38. ncbi request reprint Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:247-56. 2007
    ..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome...
  39. ncbi request reprint A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma
    Christopher W Ryan
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, Illinois, USA
    Cancer 94:2602-9. 2002
    ....
  40. ncbi request reprint Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study
    Ellis G Levine
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263 0001, USA
    Cancer 94:665-72. 2002
    ....
  41. ncbi request reprint Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer
    Richard L Schilsky
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 20:582-7. 2002
    ..The goals of this phase I study were to determine the maximum-tolerated doses of capecitabine and gemcitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT) and safety profile of this combination...
  42. ncbi request reprint A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
    Apurva A Desai
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Cancer 95:1629-36. 2002
    ....
  43. ncbi request reprint Future directions for gemcitabine in the treatment of genitourinary cancer
    Nicholas J Vogelzang
    Department of Medicine and Surgery Urology, University of Chicago Cancer Research Center, Chicago, IL 60637 1470, USA
    Semin Oncol 29:40-5. 2002
    ..These data suggest the need for further trials of gemcitabine alone or in combinations in genitourinary cancer patients...
  44. ncbi request reprint Variability in mesothelioma tumor response classification
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
    AJR Am J Roentgenol 186:1000-6. 2006
    ..In addition, the performance of a semiautomated measurement method was evaluated...
  45. ncbi request reprint Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells
    H Harlin
    Department of Pathology, The University of Chicago, IL 60637, USA
    Bone Marrow Transplant 33:491-7. 2004
    ..Our results support the hypothesis that the antitumor effects of NST may be mediated by IFN-gamma-producing CD8+ T cells, and indicate that isolation of putative tumor antigen-specific T cells, ideally, should be pursued around day +180...
  46. ncbi request reprint A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
    Amy C Peterson
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, USA
    Invest New Drugs 24:141-9. 2006
    ..We combined different doses of Bryostatin-1 with IL-2 to determine effects on clinical response rate and T cell phenotype in patients with advanced kidney cancer...
  47. ncbi request reprint Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction
    G F Fleming
    Department of Medicine, University of Chicago Medical Center, IL 60637 1470, USA
    Ann Oncol 14:1142-7. 2003
    ..Patients with hepatic or renal dysfunction are often treated with 5-fluorouracil (5-FU), but there are few data to confirm the safety of this practice...
  48. ncbi request reprint Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity
    Brian I Rini
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, U S A
    J Immunother 25:269-77. 2002
    ....
  49. ncbi request reprint Gene expression profiling of renal medullary carcinoma: potential clinical relevance
    Ximing J Yang
    Department of Pathology, The University of Chicago, Chicago, Illinois, USA
    Cancer 100:976-85. 2004
    ..To the authors' knowledge, very little is known to date regarding the underlying molecular genetics of this tumor, and no effective therapy has been established...
  50. pmc Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009
    ....
  51. ncbi request reprint Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
    Samir D Undevia
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Invest New Drugs 22:449-58. 2004
    ..The recommended phase II dose is 256 mg/m(2)/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial...
  52. ncbi request reprint Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma
    Maria S Tretiakova
    Department of Pathology, University of Chicago, Chicago, IL 60611, USA
    Am J Surg Pathol 28:69-76. 2004
    ....
  53. ncbi request reprint A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study
    W J Gradishar
    Department of Medicine, Northwestern University, Chicago, IL, USA
    Invest New Drugs 13:171-4. 1995
    ..Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma...
  54. ncbi request reprint Classification of renal neoplasms based on molecular signatures
    Ximing J Yang
    Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    J Urol 175:2302-6. 2006
    ..However, in most of these studies the investigators used renal tumors with defined histology. We analyzed a test set of renal tumors in double-blind fashion using recently established molecular profiles of renal tumors as benchmarks...
  55. ncbi request reprint Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
    Wei Peng Yong
    Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 60:811-9. 2007
    ..Hence, this study was designed to evaluate if pharmacokinetic modulation of oral etoposide with ketoconazole could lead to a favorable alteration of etoposide pharmacokinetics, and to assess the feasibility and safety of this approach...
  56. ncbi request reprint A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
    Federico Innocenti
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL 60637, USA
    Clin Pharmacol Ther 76:490-502. 2004
    ..Five partial responses were observed. Pharmacokinetic modulation of irinotecan with cyclosporine and phenobarbital has been demonstrated; further studies are necessary to evaluate whether this strategy improves the therapeutic index...
  57. ncbi request reprint Does PC-SPEs interact with warfarin?
    Nancy B Davis
    Department of Pharmaceutical Services and University of Chicago Cancer Research Center, University of Chicago, Illinois, USA
    J Urol 167:1793. 2002
  58. ncbi request reprint Selecting a secondary treatment
    Nancy B Davis
    Department of Medicine, Section of Hematology Oncology, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA
    Urol Clin North Am 30:403-14. 2003
    ..ketoconazole. and chemotherapy. At each interval, clinical trials should be offered since none of these maneuvers are proven to prolong life...
  59. ncbi request reprint Gene expression profiling of mesoblastic nephroma and Wilms tumors--comparison and clinical implications
    Jun Sugimura
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Urology 64:362-8; discussion 368. 2004
    ..MN is the most common tumor of the neonatal kidney. It occurs in a younger age group than the Wilms tumor (WT). To date, very little is known about the etiology and pathogenesis of MN...
  60. ncbi request reprint Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, USA
    J Urol 176:81-6. 2006
    ..We determined if age is a prognostic factor of clinical outcomes, specifically overall survival, disease-free survival and progression-free survival in men with hormone refractory prostate cancer...
  61. ncbi request reprint Activities and accomplishments of the cancer and leukemia group B genitourinary committee
    Eric J Small
    University of California San Francisco, San Francisco, California, USA
    Clin Cancer Res 12:3596s-600s. 2006
    ..In addition to these areas, future work of the committee will include further development of therapy for earlier-stage prostate cancer patients and bladder cancer patients...
  62. ncbi request reprint Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480
    Eric J Small
    Comprehensive Cancer Center, University of California San Francisco, 1600 Devisadero Street, Third Floor, San Francisco, CA 94115, USA
    J Clin Oncol 20:3369-75. 2002
    ..To test the hypothesis that the efficacy and toxicity of suramin in the treatment of patients with hormone-refractory prostate cancer was dose dependent...
  63. ncbi request reprint Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features
    Masayuki Takahashi
    Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Cancer Res 62:6598-605. 2002
    ..In summary, our findings suggest that the integration of gene expression data and clinical parameters could aid in detecting aggressive tumors among favorable histology WT and lead to the discovery of new drugs for WT...
  64. ncbi request reprint A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases
    Primo N Lara
    University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
    Clin Cancer Res 12:1556-63. 2006
    ..Serial serum and urine specimens were collected to assess for markers of bone metabolism...
  65. ncbi request reprint Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei 100, Taiwan
    Cancer 106:1269-75. 2006
    ..The authors developed a regimen that was designed to maintain efficacy, while reducing toxicities...
  66. ncbi request reprint Treatment options in metastatic renal carcinoma: an embarrassment of riches
    Nicholas J Vogelzang
    J Clin Oncol 24:1-3. 2006
  67. ncbi request reprint Promising systemic therapy for renal cell carcinoma
    Matthew M Cooney
    Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV 89135, USA
    Curr Treat Options Oncol 6:357-65. 2005
    ..A review of the preclinical and early clinical development of some of these novel compounds will be discussed...
  68. ncbi request reprint Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Urol 177:84-9; discussion 89. 2007
    ..We tested the efficacy and toxicity of adding paclitaxel to that regimen...
  69. ncbi request reprint The emerging role of antifolates in the treatment of malignant pleural mesothelioma
    Karim Fizazi
    Institut Gustave Roussy, Villejuif, France
    Semin Oncol 29:77-81. 2002
    ..In both trials, survival is the main endpoint. These trials will help to define the role of these new antifolates in malignant pleural mesothelioma...
  70. doi request reprint Chemotherapy for malignant pleural mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, Nevada 89135, USA
    Lancet 371:1640-2. 2008
  71. doi request reprint Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904
    Robert A Kratzke
    Division of Hematology Oncology Transplant, The University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 3:417-21. 2008
    ..This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16INK4a via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC)...
  72. ncbi request reprint Second-line chemotherapy for advanced hormone-refractory prostate cancer
    Edward G Garmey
    ArQule Inc, Woburn, MA 01801 5140, USA
    Clin Adv Hematol Oncol 6:118-22, 127-32. 2008
    ..To date, only one phase III randomized clinical trial has been completed in this setting and no therapies are FDA-approved. We review here the entirety of phase II and III data evaluating chemotherapy agents in second-line HRPC...
  73. doi request reprint Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
    Duyen T Dang
    Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Cancer Res 68:1872-80. 2008
    ..The data further show that DPP4 is a novel marker of HIF-1 induction. Altogether, these preclinical findings suggest novel clinical trials for predicting and monitoring tumor vessel responses to antiangiogenic therapy...
  74. ncbi request reprint Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27705, USA
    Cancer 110:1478-84. 2007
    ..For this reason, the correlation between an elevated body mass index (BMI) and clinical outcomes in patients with metastatic, castration-recurrent prostate cancer (CRPC) was evaluated...
  75. ncbi request reprint Signal-transduction inhibitors in renal cell carcinoma
    Nicholas J Vogelzang
    Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV, USA
    BJU Int 99:1289-95. 2007
  76. ncbi request reprint Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
    D Andrew Loblaw
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 25:1596-605. 2007
    ..To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer (PCa)...
  77. ncbi request reprint Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma
    Stanislaw M Mikulski
    Alfacell Corp, 225 Belleville Ave, Bloomfield, NJ 07003, USA
    J Clin Oncol 20:274-81. 2002
    ..Patients with unresectable and histologically confirmed malignant mesothelioma (MM) were eligible...
  78. ncbi request reprint Standard therapy for the treatment of malignant pleural mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Lung Cancer 50:S23-4. 2005
    ..This doublet-based chemotherapy regimen is now the standard therapy for the first-line treatment of MPM...
  79. ncbi request reprint Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, 00152, Rome, Italy
    Crit Rev Oncol Hematol 46:S105-15. 2003
    ..The molecular biology of these diseases is being unravelled and as knowledge accumulates, our ability to target these cancers will continue to increase...
  80. ncbi request reprint A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813
    William K Oh
    Lank Center for Geritourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:2592-8. 2003
    ..The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma...
  81. ncbi request reprint Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
    John L Marshall
    Georgetown University Medical Center Lombardi Cancer Center, Washington, DC 20007, USA
    Invest New Drugs 23:31-7. 2005
    ..The objectives were to determine the maximum tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetic profile of this orally administered agent...
  82. ncbi request reprint Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480
    Tim A Ahles
    Norris Cotton Cancer Center, Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Cancer 101:2202-8. 2004
    ..The primary purpose of the current study was to evaluate whether there was evidence of palliative effects associated with suramin at any of the three doses administered in the original clinical trial...
  83. ncbi request reprint A medical oncologist's approach to immunotherapy for advanced renal tumors: is nephrectomy indicated?
    Matthew M Cooney
    Division of Hematology Oncology, University Hospitals of Cleveland, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Curr Urol Rep 5:19-24. 2004
    ..Even with this aggressive approach, most patients eventually will die from their kidney cancer; therefore, every patient with metastatic disease should be considered for enrollment into clinical trials...
  84. ncbi request reprint Impact of race on survival in men with metastatic hormone-refractory prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 64:212-7. 2004
    ..To determine whether blacks with hormone-refractory prostate cancer have shorter survival compared with whites with the same disease...
  85. ncbi request reprint Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action
    Mario A Eisenberger
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21231 1000, USA
    Urology 63:114-9. 2004
    ..To study the safety, pharmacokinetics, biologic activity, and preliminary efficacy of the bispecific 5-alpha-reductase inhibitor (LY320236) in prostate cancer...
  86. ncbi request reprint Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer
    Celestia S Higano
    University of Washington Medical Center, Seattle, Washington 98109, USA
    Clin Cancer Res 10:1219-25. 2004
    ..In the first cycle, patients were randomized to FL or placebo. All patients received open-label FL during the next five courses. DC, anti-FL antibody, and PSA levels were measured every 15 days to assess biological activity...
  87. ncbi request reprint Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Rd, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
    J Clin Oncol 22:3003-15. 2004
    ....
  88. ncbi request reprint Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma
    Nicholas J Vogelzang
    Clin Lung Cancer 5:63-4. 2003
  89. ncbi request reprint Multimodality therapy in mesothelioma: role of chemotherapy
    Nicholas J Vogelzang
    Nevada Cancer Institute, 10, 000 West Charleston Boulevard, Suite 260, Las Vegas, NV 89135, USA
    Thorac Surg Clin 14:531-42. 2004
    ....
  90. ncbi request reprint The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480
    Daniel J George
    Divisions of Urology and Medical Oncology, Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 2771, USA
    Clin Cancer Res 11:1815-20. 2005
    ..In order to evaluate its prognostic significance in metastatic HRCaP patients, we measured IL-6 in plasma collected at baseline from patients in a large cooperative group study [Cancer and Leukemia Group B 9480 (CALGB 9480)]...
  91. ncbi request reprint Novel agents for the treatment of advanced kidney cancer
    Matthew M Cooney
    Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
    Clin Adv Hematol Oncol 2:664-70. 2004
    ..These compounds include antiangiogenic agents, raf kinase pathway inhibitors, and novel antimicrotubule agents. This review discusses some of the agents currently being explored for the treatment of advanced kidney cancer...
  92. ncbi request reprint A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy
    Nancy B Davis
    Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, Milwaukee, WI, USA
    BJU Int 96:787-90. 2005
    ..To determine the prostate-specific antigen (PSA) response and time to PSA or radiographic progression in men with prostate cancer refractory to bicalutamide and/or flutamide therapy...
  93. ncbi request reprint Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
    Mary Ellen Taplin
    University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA
    J Clin Oncol 21:2673-8. 2003
    ..Bone marrow specimens containing prostate tumor were obtained from men undergoing antiandrogen withdrawal for AR sequence analysis and clinical correlation. Materials and..
  94. ncbi request reprint New agents in the management of advanced mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Semin Oncol 32:336-50. 2005
    ..Together with the newer drugs, rapidly emerging from the laboratory to be applied in the clinic, we have the hope of making further advances in the struggle against this disease...
  95. ncbi request reprint A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    BJU Int 95:963-8. 2005
    ....
  96. ncbi request reprint Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
    H Barton Grossman
    M D Anderson Cancer Center, Houston, USA
    N Engl J Med 349:859-66. 2003
    ..We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy...
  97. ncbi request reprint Molecular subclassification of kidney tumors and the discovery of new diagnostic markers
    Masayuki Takahashi
    Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick NE, Grand Rapids, MI 49503, USA
    Oncogene 22:6810-8. 2003
    ..We have also identified in these subtypes differentially expressed genes that could have important diagnostic and therapeutic implications...
  98. ncbi request reprint Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer
    Susan Halabi
    J Clin Oncol 23:2434-5; author reply 2435. 2005
  99. ncbi request reprint Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
    J Clin Oncol 22:1025-33. 2004
    ..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy...